Executive Committee Chair Paul Carlier Chosen as Director of UIChicago’s UICentre
After 22 years at Virginia Tech, executive committee chair Paul Carlier is joining the University of Illinois Chicago's collaborative drug discovery center as their new director. He will also serve a joint appointment in the Departments of Pharmaceutical Sciences and...
Exec. Committee Member Beth Sharlow on UVA’s Fiske Drug Discovery Lab
Elizabeth R. Sharlow, Professor of Research, Pharmacology in University of Virginia's School of Medicine discusses UVA's Fiske Drug Discovery Laboratory where impactful pharmacological research occurs every day. UVA graduate and undergraduate students are learning to...
KeViRx Selected as Part of BLUE KNIGHT™ Collaboration for Global Health Preparedness
Charlottesville, Virginia - February 2022 KeViRx, Inc. (“KeViRx”) has been selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S....
Desai Grant on Factor XIa Inhibitors Funded
Umesh Desai, VaDDC executive committee member and chair of Virginia Commonwealth University's medicinal chemistry department, has just received an R61/33 grant to develop allosteric inhibitors of coagulation factor XIa. The grant, titled "Lead Identification and...
KeViRx-UVA-ODU Collaborative SBIR Grant funded
KeViRx is an early stage drug discovery company spun out of the UVA Department of Pharmacology by Elizabeth Sharlow and John Lazo and is located in Charlottesville. KeViRx was just awarded its second National Institutes of Health R43 Phase 1 Small Business Innovation...
Paul Carlier, Chair of the VaDDC, Receives Grant to Study Promising Antimalarial Drugs
Paul Carlier, a professor in the Department of Chemistry in the Virginia Tech College of Science and director of the Virginia Tech Center for Drug Discovery, and his colleagues received a $3.7 million grant from the National Institutes of Health to begin further...
Norwegian researchers have shown that a phosphatase (PRL-3) inhibitor developed by VaDDC Exec. Comm. member John Lazo might be useful to treat cancer
For the first time, researchers have shown how cancer cells reprogram themselves to produce lactic acid and to tolerate the acidic environment that exists around tumors. The finding could lead to a whole new direction for treating cancer. Read More ->
Webster Santos, Virginia Tech drug researcher receives $2.2 million NIH grant to further develop “fat burning” molecule
The Santos lab will use the grant to take his prototype molecules and synthesize derivatives to enhance their effectiveness in treating NASH (nonalcoholic steatohepatitis), which is characterized by inflammation, fat accumulation, and scarring of the liver. Read more...
VaDDC Executive Committee Member, Beth Sharlow Receives Promotion at UVA
Dr. Elizabeth Sharlow has been promoted to Professor of Research in Pharmacology effective July 1, 2020. More about Dr. Sharlow
Virginia Company, Phlow Corp. Awarded $354 million to Produce Ingredients for Covid-19 Drugs
A new Richmond-based pharmaceutical manufacturing company has received a $354 million federal contract to make the active ingredients for more than a dozen medicines used to treat patients with COVID-19. And the ingredients will be made at a pharmaceutical plant in...